

美時營運持續走強、單月自結合併營收連二月突破新台幣 10 億元

7 月自結合併營收達新台幣 11 億 2 千萬元，較去年同期增加近 5 成

Lotus Reported Unaudited July Revenues of NT\$1,117 Million, a 50% Increase YoY

The 2nd consecutive monthly sales of over NT\$1.0 billion boosted the growth momentum for H2'20

2020 年 8 月 10 日，台北

August 10th, 2020, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2020 年 7 月自結合併營收達新台幣 1,116,873 仟元，較去年同期成長近 5 成，不僅連 2 個月站穩 10 億元大關、並為連續第 5 個月營收呈現強勁的月增及年增成長；累計今年前 7 個月之合併營收已較去年同期增加近 2 成，營運前景看俏。

美時表示本月外銷業務大有斬獲，貢獻整體合併營收超過 50%，成長表現亮眼；不僅戒癮用藥 Buprenorphine/Naloxone 舌下含片之美國市占持續擴張、出貨自今年第二季初起已連續 4 個月增加，遙遙領先其他學名藥競爭廠家，旗下癌症用藥進軍國際市場亦有重大進展，全球市場版圖持續拓張、本月另於一拉丁美洲國家成功取證，故依照合約里程碑進度認列營收、並積極準備後續產品上市供貨，奠定長期營收成長基礎。

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for July 2020 was NT\$1,116,873 thousand, representing a 50% increase over the same period last year. This is the second consecutive monthly sales of more than NT\$1.0 billion and continues to be the fifth month in a row delivering stellar MoM/YoY growth in 2020.

Strong performance from Export Business, which contributed more than half of total sales, made the successful month with remarkable achievements – its leading position in market share of Buprenorphine/Naloxone film further strengthened against other generic competitors in the US and has brought in stably increasing shipment MoM for four months in a row. Moreover, several major milestones achieved by global out-licensing deals of its oncology portfolio, including an approval granted in LATAM market, and thus corresponding milestone revenue was recognized as per agreements. And those achievements will then bring in more sustainable shipment revenue going forward once the products are successfully launched to global markets.

新聞聯繫人 Contact:

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

Angela Luan, Investor Relations Director

關於美時：

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

About Lotus

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望（包括但不限於預測、目標、估算和營運計劃）之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。